Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype

Wolfram syndrome (WS), also known as a DIDMOAD (diabetes insipidus, early-onset diabetes mellitus, optic nerve atrophy and deafness) is a rare autosomal disorder caused by mutations in the Wolframin1 (<i>WFS1</i>) gene. Previous studies have revealed that glucagon-like peptide-1 receptor...

Full description

Saved in:
Bibliographic Details
Main Authors: Toomas Jagomäe, Kadri Seppa, Riin Reimets, Marko Pastak, Mihkel Plaas, Miriam A. Hickey, Kaia Grete Kukker, Lieve Moons, Lies De Groef, Eero Vasar, Allen Kaasik, Anton Terasmaa, Mario Plaas
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
wolfram syndrome
Wfs1
GLP1 receptor agonist
liraglutide
rat model
neurodegeneration
Biology (General)
QH301-705.5
Online Access:https://doaj.org/article/baf6b0dceefa49f8af4e77d5cbd8b3b4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/baf6b0dceefa49f8af4e77d5cbd8b3b4

Similar Items